GSK’s Nucala Receives Health Canada’s Approval for Severe Eosinophilic Asthma in Children and Adolescents

Shots:

• Nucala (mepolizumab) has received Health Canada’s approval as an add-on maintenance therapy for adolescents & children aged ≥6yrs. with SEA
•  The extension of NUCALA’s indication for adolescents and children aged ≥6yrs. allow the company to bring the therapy to patients and their families with limited treatment options
• Nucala is the first IL5 biologic to be approved for SAE in a pediatric population (as young as 6 yrs. old) in Canada. The therapy has received approval in 20+ markets, including the US & EU for adult patients with SAE and indicated as an approved therapy for pediatric use in patients aged 6-17yrs. as an add-on treatment for SAE

Click here ­to­ read full press release/ article | Ref: Canada Newswire | Image: GSK